- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
This study is looking into a new medicine called Nemolizumab for children aged 2 to 11 who have moderate to severe eczema. It aims to see how safe the medicine is, how well it works, and how the body handles it. It's an important step in finding new ways to help children with eczema.
For: Atopic DermatitisHungary · Spain · Poland - Active not recruitingPHASE3
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
This study looks at the long-term safety of a new medicine called Nemolizumab for people with Prurigo Nodularis. It's for those who have already tried Nemolizumab in a previous study for this skin condition.
For: Prurigo NodularisUnited States · Austria · Belgium - Active not recruitingPHASE3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.
For: Moderate-to-Severe Atopic DermatitisUnited States · Australia · Austria